- Immatics N.V. announced updated data from its Phase 1b clinical trial evaluating anzu-cel PRAME cell therapy in **16 patients** with metastatic uveal melanoma, with a data cutoff of **September 24, 2025**.  **[1809196_0000950103-25-013381_dp235990_6k.htm:0]** **[1809196_0000950103-25-013381_dp235990_ex9901.htm:1]** 
- The trial demonstrated a confirmed objective response rate (cORR) of **67% (10/15)** and a disease control rate (DCR) of **88% (14/16)**.  **[1809196_0000950103-25-013381_dp235990_6k.htm:0]** **[1809196_0000950103-25-013381_dp235990_ex9901.htm:1]** 
- Key durability metrics include a median duration of response (mDOR) of **11 months** and a median progression-free survival (mPFS) of **8.5 months**.  **[1809196_0000950103-25-013381_dp235990_6k.htm:0]** **[1809196_0000950103-25-013381_dp235990_ex9901.htm:1]** 
- Median overall survival (mOS) was not reached at a median follow-up of **14.3 months**, with an OS rate of **71% at 12 months**.  **[1809196_0000950103-25-013381_dp235990_6k.htm:0]** **[1809196_0000950103-25-013381_dp235990_ex9901.htm:1]** 
- Based on these promising clinical data, Immatics has initiated a **Phase 2 cohort** for anzu-cel in patients with metastatic uveal melanoma.  **[1809196_0000950103-25-013381_dp235990_ex9901.htm:0]** **[1809196_0000950103-25-013381_dp235990_6k.htm:1]** **[1809196_0000950103-25-013381_dp235990_ex9901.htm:2]**

Immatics N.V. highlights updated anzu-cel PRAME cell therapy data in metastatic uveal melanoma

- Immatics N.V. (IMTX) announced updated Phase 1b clinical data for its anzu-cel PRAME cell therapy in **16 patients** with metastatic uveal melanoma, presented at the ESMO 2025 Presidential Symposium.  **[1809196_c36b83510397402fa0c7f6e8eb98319b_1]** **[1809196_c36b83510397402fa0c7f6e8eb98319b_0]** 
- The therapy demonstrated strong anti-tumor activity, with a confirmed objective response rate (cORR) of **67%**, a median duration of response (mDOR) of **11.0 months**, and median overall survival (mOS) **not reached** at **14.3 months** median follow-up.  **[1809196_c36b83510397402fa0c7f6e8eb98319b_0]** **[1809196_c36b83510397402fa0c7f6e8eb98319b_2]** 
- Anzu-cel maintained a favorable tolerability profile and showed anti-tumor activity across various metastases, including in patients previously treated with TCR-based therapies.  **[1809196_c36b83510397402fa0c7f6e8eb98319b_0]** **[1809196_c36b83510397402fa0c7f6e8eb98319b_3]** 
- Following these promising results, Immatics has initiated a **Phase 2 cohort** for approximately **30 uveal melanoma patients**.  **[1809196_c36b83510397402fa0c7f6e8eb98319b_0]** **[1809196_c36b83510397402fa0c7f6e8eb98319b_3]**

Immatics (IMTX)